AR033444A1 - SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT - Google Patents
SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE ITInfo
- Publication number
- AR033444A1 AR033444A1 ARP020101068A ARP020101068A AR033444A1 AR 033444 A1 AR033444 A1 AR 033444A1 AR P020101068 A ARP020101068 A AR P020101068A AR P020101068 A ARP020101068 A AR P020101068A AR 033444 A1 AR033444 A1 AR 033444A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- nicotine
- nicotine compound
- active
- active nicotine
- Prior art date
Links
- 229960002715 nicotine Drugs 0.000 title abstract 9
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 9
- -1 NICOTINE COMPOUND Chemical class 0.000 title abstract 7
- 239000007909 solid dosage form Substances 0.000 title 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 3
- 239000002552 dosage form Substances 0.000 abstract 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 abstract 2
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 abstract 2
- 241000208125 Nicotiana Species 0.000 abstract 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 2
- 206010057852 Nicotine dependence Diseases 0.000 abstract 2
- 235000010439 isomalt Nutrition 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 150000005846 sugar alcohols Chemical class 0.000 abstract 2
- 235000019788 craving Nutrition 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una forma solida de dosificacion oral, util para la administracion oral de un compuesto activo de nicotina a través de la mucosa que comprende: a) una matriz vítrea que comprende por lo menos un azucar - alcohol sustancialmente no higroscopico capaz de formar una estructura vítrea,y b) un compuesto activo de nicotina, en una cantidad eficaz para reducir el ansia de nicotina. El azucar - alcohol puede comprender una mezcla de 1,6-GPS(6-O-alfa-D-glucopiranosil-D-sorbitol) y 1,1-GMP(1-O-alfa-D-glucopiranosil-D-manitol) en una relacion ponderal de aproximadamente 99:1 a aproximadamente 1:99. El compuesto activo de nicotina se puede seleccionar de nicotina, derivados de nicotina, y combinaciones de los mismos. Uso de un compuesto activo de nicotina para preparar la forma solida de dosificacion oral descripta en un método de aplicacion para reducir el ansia de nicotina y/o el uso del tabaco que comprende administrar oralmente la forma de dosificacion a una persona que necesite reduccion del ansia de nicotina o el uso de tabaco. Dicha forma de dosificacion puede proporcionar una concentracion de compuesto activo de nicotina en el plasma sanguíneo de por lo menos aproximadamente 6 ng/ml después de iniciar la administracion oral de la forma de dosificacionA solid oral dosage form, useful for oral administration of an active nicotine compound through the mucosa comprising: a) a vitreous matrix comprising at least one substantially non-hygroscopic sugar-alcohol capable of forming a vitreous structure, and b) an active nicotine compound, in an amount effective to reduce nicotine craving. The sugar-alcohol may comprise a mixture of 1,6-GPS (6-O-alpha-D-glucopyranosyl-D-sorbitol) and 1,1-GMP (1-O-alpha-D-glucopyranosyl-D-mannitol) in a weight ratio of about 99: 1 to about 1:99. The active nicotine compound can be selected from nicotine, nicotine derivatives, and combinations thereof. Use of an active nicotine compound to prepare the solid oral dosage form described in an application method to reduce nicotine craving and / or the use of tobacco comprising orally administering the dosage form to a person in need of craving reduction of nicotine or tobacco use. Said dosage form may provide a concentration of active nicotine compound in the blood plasma of at least about 6 ng / ml after starting oral administration of the dosage form.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27860601P | 2001-03-26 | 2001-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033444A1 true AR033444A1 (en) | 2003-12-17 |
Family
ID=23065632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101068A AR033444A1 (en) | 2001-03-26 | 2002-03-22 | SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1372392A4 (en) |
| JP (1) | JP2004525928A (en) |
| CN (2) | CN1553771A (en) |
| AR (1) | AR033444A1 (en) |
| AU (1) | AU2002252470B2 (en) |
| BR (1) | BR0208382A (en) |
| CA (1) | CA2440713A1 (en) |
| MX (1) | MXPA03008762A (en) |
| NZ (1) | NZ528167A (en) |
| PL (1) | PL364621A1 (en) |
| WO (1) | WO2002076211A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Composition for treating insomnia |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| WO2005009386A2 (en) * | 2003-07-24 | 2005-02-03 | Smithkline Beecham Corporation | Orally dissolving films |
| GB0320854D0 (en) | 2003-09-05 | 2003-10-08 | Arrow No 7 Ltd | Buccal drug delivery |
| AU2004289248B2 (en) | 2003-11-07 | 2012-05-03 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
| US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
| JP4964773B2 (en) * | 2004-08-11 | 2012-07-04 | クラフト・フーヅ・グローバル・ブランズ・エルエルシー | Sensory initiator composition and delivery system thereof |
| JP5254616B2 (en) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| CA2670886A1 (en) * | 2006-12-01 | 2008-06-12 | Cima Labs Inc. | Oral transmucosal nicotine dosage form |
| GB2468424B (en) * | 2007-04-02 | 2011-11-09 | Parkinson S Inst | Methods and compositions for reduction of side effects of therapeutic treatments |
| ES2521494T3 (en) | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Methods and compositions for reducing the side effects of therapeutic treatments |
| DE102008012015A1 (en) * | 2008-03-01 | 2009-09-10 | Südzucker AG Mannheim/Ochsenfurt | Improved isomalt-containing compresses and processes for their preparation |
| JP5845194B2 (en) * | 2010-02-18 | 2016-01-20 | サッカー・ジャティン・ヴァサントＴＨＡＫＫＡＲ， Ｊａｔｉｎ Ｖａｓａｎｔ | Nicotine-containing soft gelatin troche |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| UA112974C2 (en) | 2010-09-16 | 2016-11-25 | Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид | NICOTINE COMPOSITION (OPTIONS) |
| CA2841785A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| US9474303B2 (en) * | 2011-09-22 | 2016-10-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
| US9084439B2 (en) | 2011-09-22 | 2015-07-21 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
| US9629392B2 (en) | 2011-09-22 | 2017-04-25 | R.J. Reynolds Tobacco Company | Translucent smokeless tobacco product |
| US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
| US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
| US9044035B2 (en) * | 2012-04-17 | 2015-06-02 | R.J. Reynolds Tobacco Company | Remelted ingestible products |
| AR096223A1 (en) * | 2013-05-10 | 2015-12-16 | Glaxosmithkline Llc | NICOTINE PILL FOR ORAL ADMINISTRATION |
| CN104132895B (en) * | 2014-07-08 | 2017-08-25 | 国家烟草质量监督检验中心 | The buffer system of total alkaloid tobacco and tobacco product is determined suitable for continuous flow method |
| AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| JP2018511127A (en) | 2015-03-12 | 2018-04-19 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | Craving input and support system |
| EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| SE541358C2 (en) * | 2017-05-30 | 2019-08-13 | Enorama Pharma Ab | Nicotine-containing chewing gum compositions |
| WO2019232077A1 (en) | 2018-05-29 | 2019-12-05 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| MA54245A (en) | 2018-11-16 | 2022-02-23 | Morningside Venture Investments Ltd | TRANSDERMAL TEMPERATURE-REGULATING DRUG DELIVERY SYSTEM |
| ES3034287T3 (en) * | 2019-06-07 | 2025-08-14 | Philip Morris Products Sa | Nicotine pouch product |
| EP4090314A1 (en) * | 2020-01-15 | 2022-11-23 | McNeil AB | Lozenge |
| US20220313678A1 (en) * | 2021-04-06 | 2022-10-06 | Altria Client Services Llc | Spray dried nicotine for inclusion in oral products |
| USD1081739S1 (en) | 2021-04-06 | 2025-07-01 | Altria Client Services Llc | Die for gum forming |
| US12295412B2 (en) | 2022-01-28 | 2025-05-13 | Altria Client Services Llc | Oral pouch product |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| US5549906A (en) * | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| DE19536394A1 (en) * | 1995-09-29 | 1997-04-03 | Basf Ag | Solid pharmaceutical forms, obtainable by extrusion of a polymer-active substance melt containing isomalt |
| DE19639342C2 (en) * | 1996-09-25 | 1998-07-16 | Suedzucker Ag | Chewing gum containing a sweetener |
| US6322806B1 (en) * | 1999-04-06 | 2001-11-27 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations including tableted center |
-
2002
- 2002-03-22 AR ARP020101068A patent/AR033444A1/en unknown
- 2002-03-22 AU AU2002252470A patent/AU2002252470B2/en not_active Ceased
- 2002-03-22 PL PL02364621A patent/PL364621A1/en not_active Application Discontinuation
- 2002-03-22 CN CNA028073339A patent/CN1553771A/en active Pending
- 2002-03-22 BR BR0208382-5A patent/BR0208382A/en not_active IP Right Cessation
- 2002-03-22 CN CNA2008101253651A patent/CN101301275A/en active Pending
- 2002-03-22 JP JP2002574739A patent/JP2004525928A/en active Pending
- 2002-03-22 EP EP02721544A patent/EP1372392A4/en not_active Withdrawn
- 2002-03-22 NZ NZ528167A patent/NZ528167A/en not_active IP Right Cessation
- 2002-03-22 WO PCT/US2002/008914 patent/WO2002076211A1/en active IP Right Grant
- 2002-03-22 CA CA002440713A patent/CA2440713A1/en not_active Abandoned
- 2002-03-22 MX MXPA03008762A patent/MXPA03008762A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| NZ528167A (en) | 2005-04-29 |
| CN1553771A (en) | 2004-12-08 |
| MXPA03008762A (en) | 2004-02-18 |
| CA2440713A1 (en) | 2002-10-03 |
| WO2002076211A1 (en) | 2002-10-03 |
| CN101301275A (en) | 2008-11-12 |
| AU2002252470B2 (en) | 2008-05-22 |
| EP1372392A1 (en) | 2004-01-02 |
| PL364621A1 (en) | 2004-12-13 |
| BR0208382A (en) | 2004-06-15 |
| EP1372392A4 (en) | 2004-06-23 |
| JP2004525928A (en) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033444A1 (en) | SOLID DOSAGE FORM FOR THE ORAL ADMINISTRATION OF AN ACTIVE NICOTINE COMPOUND, THROUGH THE MUCOSE AND USE OF AN ACTIVE NICOTINE COMPOUND TO PREPARE IT | |
| EP0735859B1 (en) | A pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| AR040722A1 (en) | FORMULATIONS AND DOSAGE FORMS FOR THE CONTROLLED ADMINISTRATION OF TOPIRAMATO | |
| AR037592A1 (en) | PHARMACEUTICAL FORMULATIONS OF 5,7,14-TRIAZATETRACICLO (10.3.1.02,11.04,9) -HEXADECA-2 (11), 3,5,7,9-PENTAENO | |
| NO993520D0 (en) | Dosage forms and methods for improving erectile dysfunction | |
| DE69916486D1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE WITH FAST TRANSMUCOSAL ABSORPTION | |
| AR059324A2 (en) | A solid form of oral dosing | |
| CO5560558A2 (en) | USE OF A CELECOXIB COMPOSITION FOR PAIN RELIEF FAST | |
| DK1257254T3 (en) | Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease | |
| RU2008101513A (en) | FILMS DISSOLVING IN THE ORAL CAVITY | |
| CO5261582A1 (en) | VALDECOXIB COMPOSITIONS | |
| CO5680109A1 (en) | COMPOUNDS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | |
| ES2096781T3 (en) | COMPOSITIONS OF CONTROLLED RELEASE OXICODONS. | |
| Pryor | Vardenafil: update on clinical experience | |
| UY29905A1 (en) | PHARMACEUTICAL FORMULATION OF ORAL ABSORPTION AND ITS METHOD OF ADMINISTRATION | |
| GR1000380B (en) | Analgesic compositions | |
| CL2009001899A1 (en) | Pharmaceutical composition comprising: i) an at1 receptor antagonist or a salt, ii) an insulin sensitizer or a salt and iii) a pharmaceutically acceptable carrier; use for the prevention, delay of progress or treatment of hypertension, diabetes, among others (div. sol. 2034-01). | |
| ATE388687T1 (en) | MEDICINAL ADMINISTRATION OF NICOTINE IN THE FORM OF CHEWING GUM | |
| ECSP055606A (en) | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION BY ORAL OF ANALGESIC MEDICINES | |
| AR033688A1 (en) | RECONSTITUABLE PARENTERAL COMPOSITION | |
| CO5280073A1 (en) | COMPOSITIONS | |
| DE50203456D1 (en) | DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS | |
| AR015744A1 (en) | USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY | |
| RU2007133435A (en) | METHOD OF COMBINED TREATMENT AND APPLICABLE FOR THIS COMBINATION OF MEDICINES | |
| ES2175663T3 (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |